Topline results from Boehringer's Phase III IPF ... - Boehringer Ingelheim
WEBSep 16, 2024 · Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] (FVC) at week 52 versus placebo. FVC is a measure of lung function. 1 Based on these results, Boehringer Ingelheim will submit the new drug application for nerandomilast for the treatment of IPF to the US Food & Drug ...
Press Releases - Boehringer Ingelheim
WEBFind the latest press releases from Boehringer Ingelheim on animal health, prescription medicine, pipeline and corporate news.
Boehringer Ingelheim GmbH - The New York Times
WEBNews about Boehringer Ingelheim GmbH. Commentary and archival information about Boehringer Ingelheim GmbH from The New York Times.
Boehringer Ingelheim reports strong growth in 2023 and …
WEBApr 16, 2024 · Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
First half of 2024: Boehringer Ingelheim progresses
WEBJul 18, 2024 · Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it reached major milestones...
Boehringer Ingelheim reports strong growth in 2023 and
WEBApr 16, 2024 · Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned. Research & Development (R&D) investments...
First half of 2023: Boehringer Ingelheim sees strong growth and ...
WEBAug 1, 2023 · INGELHEIM, Germany-- (BUSINESS WIRE)--Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health...
Boehringer Ingelheim Begins Clinical Development of First-In …
WEBMay 9, 2023 · Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1
Small-molecule drug shows potential for hard to treat cancers
WEB7 hours ago · Discovering ACBI3. To get to this compound, the team, co-led by Johannes Popow, Christiane Kofink and Andreas Gollner at Boehringer Ingelheim in Vienna and William Farnaby at Dundee (co-first ...
First half of 2024: Boehringer Ingelheim progresses pipeline at …
WEBJul 18, 2024 · Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it reached major milestones...
Skip to content